Boostrix Suspension
NDC Package 50090-1377-0
Package Information
Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) suspension is bOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older. This formulation utilizes a suspension delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-1377 and is authorized under FDA application BLA125106.
Identification & Billing
- RxCUI: 1300368 - Tdap (generic for Boostrix) 0.5 ML Prefilled Syringe
- RxCUI: 1300368 - 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
- RxCUI: 1300368 - Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 8 MCG / Bordetella pertussis pertactin vaccine, inactivated 2.5 MCG / Bordetella pertussis toxoid vaccine, inactivated 8 MCG / diphtheria toxoid vaccine, inactivated 2.5 UNT / tetanus toxoid vaccine, inactivated 5 UNT per 0.5 ML Prefilled Syringe
- RxCUI: 1300368 - Tdap (tetanus toxoid vaccine, inactivated 5 UNT / diphtheria toxoid vaccine, inactivated 2.5 UNT / acellular pertussis vaccine, inactivated 18.5 MCG) per 0.5 ML Prefilled Syringe
- RxCUI: 1300368 - tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap generic for Boostrix) 0.5 ML Prefilled Syringe
Clinical Specifications
- BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) 8 ug/.5mL
- BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED) 2.5 ug/.5mL
- BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED) 8 ug/.5mL
- CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) 5 [iU]/.5mL
- CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) 2.5 [iU]/.5mL
- Actively Acquired Immunity - [PE] (Physiologic Effect)
- Actively Acquired Immunity - [PE] (Physiologic Effect)
- Diphtheria Toxoid - [CS]
- Inactivated Bordetella Pertussis Vaccine - [EPC] (Established Pharmacologic Class)
- Inactivated Clostridium Tetani Vaccine - [EPC] (Established Pharmacologic Class)
- Inactivated Corynebacterium Diphtheriae Vaccine - [EPC] (Established Pharmacologic Class)
- Pertussis Vaccine - [CS]
- Tetanus Toxoid - [CS]
- Vaccines, Inactivated - [CS]
Regulatory & Marketing
Hierarchy Structure
- 50090 - A-s Medication Solutions
- 50090-1377 - Boostrix
- 50090-1377-0 - 10 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE (50090-1377-2)
- 50090-1377 - Boostrix
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (50090-1377). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50090-1377-0 identifies a specific commercial package of 10 syringe in 1 carton / .5 ml in 1 syringe (50090-1377-2) of Boostrix, a vaccine label labeled by A-s Medication Solutions. This suspension is formulated for intramuscular use and contains bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated); bordetella pertussis pertactin antigen (formaldehyde inactivated); bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated); clostridium tetani toxoid antigen (formaldehyde inactivated); corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on July 24, 2009. The current certification is valid through December 31, 2026.
How is this A-s Medication Solutions product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090137700. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.